Brenner DR, Gillis J, Demers AA, Ellison LF, Billette JM, Zhang SX, Liu JL, Woods RR, Finley C, Fitzgerald N, Saint-Jacques N, Shack L, Tuner D (2024) Projected estimates of cancer in Canada in 2024. CMAJ 196(18):E615–E623. https://doi.org/10.1503/cmaj.240095

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics 2024. CA Cancer J Clin 74(1):12–49. https://doi.org/10.3322/caac.21820

Article  PubMed  Google Scholar 

National Cancer Institute (2024) Surveillance Epidemiology and End Results (SEER) Program. Cancer Stat Facts: Female Breast Cancer. https://seer.cancer.gov/statfacts/html/breast.html Accessed 31 Aug 2024

Dufour O, Houvenaeghel G, Classe JM, Cohen M, Faure C, Mazouni C, Jouve E, Darai E, Azuar A, Gimbergues P, Gonclaves A, de Nonneville A (2023) Early breast cancer in women aged 35 years or younger: a large national multicenter French population-based case control-matched analysis. Breast 68:163–172. https://doi.org/10.1016/j.breast.2023.02.004

Article  PubMed  PubMed Central  Google Scholar 

Szollár A, Újhelyi M, Polgár C, Oláh E, Pukancsik D, Rubovszky G, Udvarhelyi N, Kovács T, Ákos Sávolt A, István Kenessey I, Mátrai Z (2019) A long-term retrospective comparative study of the oncological outcomes of 598 very young (≤35 years) and young (36–45 years) breast cancer patients. Eur J Surg Oncol 45(11):2009–2015. https://doi.org/10.1016/j.ejso.2019.06.007

Article  PubMed  Google Scholar 

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torris R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M (2010) Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21(10):1974–1981. https://doi.org/10.1093/annonc/mdq072

Article  CAS  PubMed  Google Scholar 

Brenner DR, Brockton NT, Kotsopoulos J, Cotterchio M, Boucher BA, Courneya KS, Knight AJ, Olivotto IA, Quan ML, Fridenreich CM (2016) Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control 27(4):459–472. https://doi.org/10.1007/s10552-016-0726-5

Article  PubMed  PubMed Central  Google Scholar 

Eiriz IF, Vaz Batista M, Cruz Tomás T, Neves MT, Guerra-Pereira N, Braga S (2021) Breast cancer in very young women-a multicenter 10-year experience. ESMO Open 6(1):100029. https://doi.org/10.1016/j.esmoop.2020.100029

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finch A, Wang M, Fine A, Atri L, Khalouei S, Pupavac M, Rosen B, Eisen A, Elser C, Charames G, Metcalfe K, Chang MC, Narod SA, Lerner-Eillis J (2016) Genetic testing for BRCA1 and BRCA2 in the Province of Ontario. Clin Genet 89(3):304–311. https://doi.org/10.1111/cge.12647

Article  CAS  PubMed  Google Scholar 

van den Broek AJ, de Ruiter K, van’t Veer LJ, Tollenaar RAEM, van Leeuwen FE, Verhoef S, Schmidt MK (2015) Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. Eur J Hum Genet 23(5):588–595. https://doi.org/10.1038/ejhg.2014.161

Article  CAS  PubMed  Google Scholar 

Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, Borges VF, Larsen B, Garber JE, Partridge AH (2016) BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol 2(6):730–736. https://doi.org/10.1001/jamaoncol.2015.5941

Article  PubMed  PubMed Central  Google Scholar 

Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, Wright F, Lerner-Ellis J, McCuaig J, Graham T, Sun P, Akbari M, Narod SA (2021) Rapid genetic testing for BRCA1 and BRCA2 mutations at the time of breast cancer diagnosis: an observational study. Ann Surg Oncol 28(4):2219–2226. https://doi.org/10.1245/s10434-020-09160-8

Article  PubMed  Google Scholar 

Dettwyler SA, Thull DL, McAuliffe PF, Steiman JG, Johnson RR, Diego EJ, Mai PL (2022) Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy. Breast Cancer Res Treat 194(2):393–401. https://doi.org/10.1007/s10549-022-06619-y

Article  CAS  Google Scholar 

Chiba A, Hoskin TL, Hallberg EJ, Cogswell JA, Heins CN, Couch FJ, Boughey JC (2016) Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1/BRCA2 mutation carriers with breast cancer. Ann Surg Oncol 23(10):3232–3238. https://doi.org/10.1245/s10434-016-5328-7

Article  PubMed  PubMed Central  Google Scholar 

Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M, Jagsi R, Katz SJ (2020) Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer. JAMA Oncol 6(4):e196400. https://doi.org/10.1001/jamaoncol.2019.6400

Article  PubMed  PubMed Central  Google Scholar 

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Conte P (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523–533. https://doi.org/10.1056/NEJMoa1706450

Article  CAS  PubMed  Google Scholar 

Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE (2021) Adjuvant olaparib for patients with BRCA1 or BRCA2 mutated breast cancer. N Engl J Med 384(25):2394–2405. https://doi.org/10.1056/NEJMoa2105215

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Blum JL (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763. https://doi.org/10.1056/NEJMoa1802905

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ulrich ND, Raja NS, Moravek MB (2022) A review of fertility preservation in patients with breast cancer. Best Pract Res Clin Obstet Gynaecol 82:60–68. https://doi.org/10.1016/j.bpobgyn.2022.01.004

Article  PubMed  Google Scholar 

Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Peppercorn J, Borges VF, Come S, Snow C, Ginsburg ES, Partridge AH (2023) Fertility preferences and practices among young women with breast cancer: germline genetic carriers versus noncarriers. Clin Breast Cancer 23(3):317–323. https://doi.org/10.1016/j.clbc.2022.12.012

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network (NCCN) (2024) Clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 3. National Comprehensive Cancer Network

McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH (2018) Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. J Med Genet 55(9):571–577. https://doi.org/10.1136/jmedgenet-2018-105472

Article  PubMed  Google Scholar 

Cancer Care Ontario (2022) Hereditary cancer testing eligibility criteria: version 3. https://www.cancercareontario.ca/sites/ccocancercare/files/guidelines/full/HCTEligibilityCriteriaV3_0.pdf. Accessed 31 Aug 2024

Childers CP, Childers KK, Maggard-Gibbons M, Macinko J (2017) National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 35(34):3800–3806. https://doi.org/10.1200/JCO.2017

Article  PubMed  PubMed Central  Google Scholar 

Kehl KL, Shen C, Litton JK, Arun B, Giordano SH (2016) Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat 155(1):165–173. https://doi.org/10.1007/s10549-015-3658-y

Article  CAS  PubMed  Google Scholar 

Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K (2016) Adherence patterns to national comprehensive cancer network guidelines for referral of women with breast cancer to genetics professionals. Am J Clin Oncol 39(4):363–367. https://doi.org/10.1097/COC.0000000000000073

Article  PubMed  Google Scholar 

Kurian AW, Abrahamse P, Furgal A, Ward KC, Hamilton AS, Hodan R, Tocco R, Liu L, Berek JS, Hoang L, Yussuf A, Susswein L, Esplin ED, Slavin TP, Gomez AL, Hofer TP, Katz SJ (2023) Germline genetic testing after cancer diagnosis. JAMA 330(1):43–51. https://doi.org/10.1001/jama.2023.9526

Article  CAS  PubMed  PubMed Central  Google Scholar 

Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durvan LT, Jones L, Evans G, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 19(2):169–180. https://doi.org/10.1016/S1470-2045(17)30891-4

Article